Brain Aneurysm Clipping with the Leica M530 OH6 Neurosurgical Microscope

Recording of a brain aneurysm clipping by Vik Udani, MD, Division of Neurosurgery, Senta Clinic, San Diego, CA.



Patient is a 38-year-old female with a history of hypertension and migraines. She was found to have an 8mm unruptured right middle cerebral artery aneurysm and underwent a right frontal temporal craniotomomy for aneurysm clipping.

Dr. Udani on the M530 OH6 surgical microscope: “One of my favorite aspects of the OH6 is the amount of illumination on the surgical field. The light transmission provides sharp, crisp, bright images of fine vascular structures, which greatly enhances my visualization throughout the entire procedure. The improved illumination as well as the integrated camera also provides greater clarity when using the ICG activated filter giving me greater confidence in my surgical decisions.”

Watch this video and experience for yourself: Bright 400-Watt Xenon light system for concentrated light beam into deep cavities; high resolution and depth of focus with exclusive FusionOptics technology.

Find out more about the M530 OH6 premium surgical microscope for neurosurgery: Leica M530 OH6 with FusionOptics

Case and video provided courtesy of Vik Udani, MD.


Contact DB Surgical for More Information.

Republished from Leica Microsystems.

Leica Microsystems Receives Award as Technology Leader

Wetzlar, Germany. The research and consulting company Frost & Sullivan has recognized Leica Microsystems’ newly acquired Optical Coherence Tomography (OCT) company Bioptigen of Morrisville, North Carolina, USA, as a technology leader and pioneer of the North American ophthalmic imaging industry. The Frost & Sullivan Award ceremony took place January 13, 2016 in San Diego, USA.

In their appraisal, Frost & Sullivan calls attention to the value represented in Bioptigen’s OCT solutions: “Frost & Sullivan recognizes the enormous value addition Bioptigen’s Envisu Spectral Domain (SD)-OCT platform brings to ophthalmic imaging.”

Particularly emphasized are the highly customizable imaging solutions for pre-clinical and clinical applications. Bioptigen is offering hand-held OCT imaging capabilities bringing OCT directly to the patient. Quick and sensitive real-time OCT imaging minimizes the challenges of comprehensive eye examinations with supine and non-compliant patients, such as infants and children. Bioptigen offers the world’s only hand-held OCT solution approved by the FDA for use as an aid in the diagnosis of physiological and pathologic conditions of the eye.

Markus Lusser, President of Leica Microsystems, expressed his pride at the award: “Leica Microsystems is honored that Bioptigen has been selected for the Frost & Sullivan Award. It is tangible proof of the Bioptigen team’s dedication to creativity, innovation, and the constant exploration of growth potential in the vision healthcare market.”

Bioptigen develops and manufactures innovative OCT systems and software and provides products for clinical as well as translational research applications globally. Bioptigen currently markets the Envisu OCT for pediatric ophthalmic imaging applications, and a family of OCT imaging products for vision science research. Notably, in December 2015, the company received FDA clearance for EnFocus, an innovative OCT ophthalmic imaging solution to upgrade surgical microscopes with intrasurgical OCT capabilities directly integrated in the light path of the microscope. Bioptigen was acquired by Leica Microsystems in 2015.



 

 


Contact DB Surgical for more information.

Republished from Leica Microsystems